VST BIO Secures $45 Million to Advance Stroke Therapeutics with VB-001 Development
- VST BIO secured $45 million in Series A financing to advance its stroke therapeutic program, VB-001.
- The funding aims to propel VB-001 into first-in-human studies for acute ischemic stroke by 2026.
- William Sessa joins VST BIO's Board, bringing expertise to support VB-001's clinical transition and development.
VST BIO Closes Series A Financing to Advance Stroke Therapeutics
VST BIO Corporation, a biotech firm based in San Diego, announces the successful closure of its Series A financing, securing $45 million from backers including Coefficient Giving. This funding marks a significant milestone since the company's inception in 2020 and is earmarked for advancing its flagship program, VB-001, towards first-in-human studies expected to begin in 2026. The ambitious program targets acute ischemic stroke and aims to establish VB-001 as a significant therapeutic option based on promising preclinical results. The company’s leadership, including CEO Dr. Krisztina Zsebo, emphasizes the importance of this financing in bolstering their platform and overall development capabilities.
The potential of VB-001 stems from its innovative design as a monoclonal antibody intended to address the underlying causes of stroke, particularly vascular inflammation. With this funding, VST BIO is poised to refine its approach and propel VB-001 toward clinical trials that could transform treatment protocols for acute ischemic stroke patients. VST BIO’s strategic focus on first-in-class treatments speaks volumes about the company's commitment to addressing unmet medical needs in vascular health, showcasing their intent to lead in advancing therapies that could benefit a broad range of conditions linked to inflammation and edema.
In tandem with the financing announcement, VST BIO makes a strategic appointment of William Sessa to its Board of Directors. Sessa brings invaluable expertise from his previous role as Senior Vice President and Chief Scientific Officer for Internal Medicine at Pfizer, where he successfully advanced drug development programs targeting metabolic and vascular diseases. His experience will be instrumental as VST BIO endeavors to transition VB-001 into the clinical phase and explore its potential across a spectrum of vascular-related health challenges including sepsis and cytokine release syndrome.
Along with the financing and expert appointments, VST BIO reinforces its position as a forward-thinking player in the biotechnology sector, striving to develop innovative solutions for acute ischemic stroke and other significant health issues. With expectations set high for the lead program VB-001, the company invites stakeholders and interested parties to discover more about its objectives by visiting their website at www.vst-bio.com.